211 related articles for article (PubMed ID: 29119867)
1. Targeted macrophages delivery of rifampicin-loaded lipid nanoparticles to improve tuberculosis treatment.
Vieira AC; Magalhães J; Rocha S; Cardoso MS; Santos SG; Borges M; Pinheiro M; Reis S
Nanomedicine (Lond); 2017 Dec; 12(24):2721-2736. PubMed ID: 29119867
[TBL] [Abstract][Full Text] [Related]
2. Mannosylated solid lipid nanoparticles for the selective delivery of rifampicin to macrophages.
Vieira ACC; Chaves LL; Pinheiro M; Lima SAC; Ferreira D; Sarmento B; Reis S
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):653-663. PubMed ID: 29433346
[TBL] [Abstract][Full Text] [Related]
3. Rifampicin loaded mannosylated cationic nanostructured lipid carriers for alveolar macrophage-specific delivery.
Song X; Lin Q; Guo L; Fu Y; Han J; Ke H; Sun X; Gong T; Zhang Z
Pharm Res; 2015 May; 32(5):1741-51. PubMed ID: 25407545
[TBL] [Abstract][Full Text] [Related]
4. Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis.
Pinheiro M; Ribeiro R; Vieira A; Andrade F; Reis S
Drug Des Devel Ther; 2016; 10():2467-75. PubMed ID: 27536067
[TBL] [Abstract][Full Text] [Related]
5. Functionalized rifampicin-loaded nanostructured lipid carriers enhance macrophages uptake and antimycobacterial activity.
Carneiro SP; Carvalho KV; de Oliveira Aguiar Soares RD; Carneiro CM; de Andrade MHG; Duarte RS; Dos Santos ODH
Colloids Surf B Biointerfaces; 2019 Mar; 175():306-313. PubMed ID: 30553206
[TBL] [Abstract][Full Text] [Related]
6. Newly synthesized surfactants for surface mannosylation of respirable SLN assemblies to target macrophages in tuberculosis therapy.
Maretti E; Costantino L; Buttini F; Rustichelli C; Leo E; Truzzi E; Iannuccelli V
Drug Deliv Transl Res; 2019 Feb; 9(1):298-310. PubMed ID: 30484257
[TBL] [Abstract][Full Text] [Related]
7. Mannosylated graphene oxide as macrophage-targeted delivery system for enhanced intracellular M.tuberculosis killing efficiency.
Pi J; Shen L; Shen H; Yang E; Wang W; Wang R; Huang D; Lee BS; Hu C; Chen C; Jin H; Cai J; Zeng G; Chen ZW
Mater Sci Eng C Mater Biol Appl; 2019 Oct; 103():109777. PubMed ID: 31349400
[TBL] [Abstract][Full Text] [Related]
8. Gelatin nanocarriers as potential vectors for effective management of tuberculosis.
Saraogi GK; Gupta P; Gupta UD; Jain NK; Agrawal GP
Int J Pharm; 2010 Jan; 385(1-2):143-9. PubMed ID: 19819315
[TBL] [Abstract][Full Text] [Related]
9. Development and Characterization of Nanoembedded Microparticles for Pulmonary Delivery of Antitubercular Drugs against Experimental Tuberculosis.
Goyal AK; Garg T; Rath G; Gupta UD; Gupta P
Mol Pharm; 2015 Nov; 12(11):3839-50. PubMed ID: 26436948
[TBL] [Abstract][Full Text] [Related]
10. Mannose-conjugated chitosan nanoparticles loaded with rifampicin for the treatment of visceral leishmaniasis.
Chaubey P; Mishra B
Carbohydr Polym; 2014 Jan; 101():1101-8. PubMed ID: 24299880
[TBL] [Abstract][Full Text] [Related]
11. Formulation, optimization, and characterization of rifampicin-loaded solid lipid nanoparticles for the treatment of tuberculosis.
Chokshi NV; Khatri HN; Patel MM
Drug Dev Ind Pharm; 2018 Dec; 44(12):1975-1989. PubMed ID: 30058392
[TBL] [Abstract][Full Text] [Related]
12. Targeted delivery of rifampicin to tuberculosis-infected macrophages: design, in-vitro, and in-vivo performance of rifampicin-loaded poly(ester amide)s nanocarriers.
Amarnath Praphakar R; Munusamy MA; Sadasivuni KK; Rajan M
Int J Pharm; 2016 Nov; 513(1-2):628-635. PubMed ID: 27693734
[TBL] [Abstract][Full Text] [Related]
13. Inhalable chitosan nanoparticles as antitubercular drug carriers for an effective treatment of tuberculosis.
Garg T; Rath G; Goyal AK
Artif Cells Nanomed Biotechnol; 2016 May; 44(3):997-1001. PubMed ID: 25682840
[TBL] [Abstract][Full Text] [Related]
14. In vitro controlled release of Rifampicin through liquid-crystalline folate nanoparticles.
Parmar R; Misra R; Mohanty S
Colloids Surf B Biointerfaces; 2015 May; 129():198-205. PubMed ID: 25863713
[TBL] [Abstract][Full Text] [Related]
15. Improved antibacterial function of Rifampicin-loaded solid lipid nanoparticles on Brucella abortus.
Ghaderkhani J; Yousefimashouf R; Arabestani M; Roshanaei G; Asl SS; Abbasalipourkabir R
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1181-1193. PubMed ID: 30942627
[TBL] [Abstract][Full Text] [Related]
16. Poly(lactic-
Maghrebi S; Joyce P; Jambhrunkar M; Thomas N; Prestidge CA
ACS Appl Mater Interfaces; 2020 Feb; 12(7):8030-8039. PubMed ID: 32013379
[TBL] [Abstract][Full Text] [Related]
17. Surface engineered lipid nanoparticle-mediated site-specific drug delivery system for the treatment of inflammatory bowel disease.
Sinhmar GK; Shah NN; Rawal SU; Chokshi NV; Khatri HN; Patel BM; Patel MM
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):565-578. PubMed ID: 29661024
[TBL] [Abstract][Full Text] [Related]
18. Lipid nanoparticles coated with chitosan using a one-step association method to target rifampicin to alveolar macrophages.
Vieira ACC; Chaves LL; Pinheiro M; Lima SC; Neto PJR; Ferreira D; Sarmento B; Reis S
Carbohydr Polym; 2021 Jan; 252():116978. PubMed ID: 33183580
[TBL] [Abstract][Full Text] [Related]
19. Matryoshka-type gastro-resistant microparticles for the oral treatment of Mycobacterium tuberculosis.
Andreu V; Larrea A; Rodriguez-Fernandez P; Alfaro S; Gracia B; Lucía A; Usón L; Gomez AC; Mendoza G; Lacoma A; Dominguez J; Prat C; Sebastian V; Ainsa JA; Arruebo M
Nanomedicine (Lond); 2019 Mar; 14(6):707-726. PubMed ID: 30734643
[TBL] [Abstract][Full Text] [Related]
20. Mucoadhesive chitosan-coated solid lipid nanoparticles for better management of tuberculosis.
Vieira ACC; Chaves LL; Pinheiro S; Pinto S; Pinheiro M; Lima SC; Ferreira D; Sarmento B; Reis S
Int J Pharm; 2018 Jan; 536(1):478-485. PubMed ID: 29203137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
